Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Migraine Prevention (Dec 2020)

Posted by Matt Breese on Dec 26, 2020

Find me on:

According to our recent payer coverage analysis for migraine prevention treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for migraine prevention treatments shows that under the pharmacy benefit, almost 58% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Migraine Prevention-4Q2020Data snapshot as of Q4 2020

Trends: In February 2020, the FDA approved H. Lundbeck A/S's Vyepti (eptinezumab-jjmr) for the preventive treatment of migraine in adults. The recommended dose is 100 mg every three months. Vyepti is the first FDA-approved intravenous treatment for migraine prevention, according to the company's news release.  

To read the full Reality Check on Migraine Prevention treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing